Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)

Research output: Contribution to journalArticle

Abstract

Scleromyxedema is a rare disease characterized by mucin deposition in skin and other organs and the production of a monoclonal IgG protein. Herein we describe our experience with a series of patients with this condition and specifically focus on the use of intravenous immunoglobulin (IVIG) for long-term management. We retrospectively reviewed the clinical manifestations of 10 patients evaluated at our center, highlighting the potential organ involvement. We found that systemic manifestations of the disease are common and often mimic those seen in systemic sclerosis. Eight of the 10 patients were treated with IVIG with a 100% complete or partial response rate. Treatment was initiated at a dose of 2 g/kg (total dose, divided over 2-5 days) for 6 months of initial therapy. In each case where IVIG was used, maintenance infusions are required to preserve disease control. We highlight the long-term use of this medication in several cases. We discuss the potential therapeutic benefit of IVIG in this condition, where the pathophysiology of the disease is poorly understood, and underscore new data on the potential mechanism of action of IVIG therapy.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalMedicine
Volume87
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Scleromyxedema
Intravenous Immunoglobulins
Passive Immunization
Systemic Scleroderma
Mucins
Rare Diseases
Action Potentials
Therapeutics
Immunoglobulin G
Maintenance
Skin
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Scleromyxedema : A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). / Blum, Marissa; Wigley, Fredrick; Hummers, Laura.

In: Medicine, Vol. 87, No. 1, 01.2008, p. 10-20.

Research output: Contribution to journalArticle

@article{c47485362870442282cb6907c6e4c0c3,
title = "Scleromyxedema: A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)",
abstract = "Scleromyxedema is a rare disease characterized by mucin deposition in skin and other organs and the production of a monoclonal IgG protein. Herein we describe our experience with a series of patients with this condition and specifically focus on the use of intravenous immunoglobulin (IVIG) for long-term management. We retrospectively reviewed the clinical manifestations of 10 patients evaluated at our center, highlighting the potential organ involvement. We found that systemic manifestations of the disease are common and often mimic those seen in systemic sclerosis. Eight of the 10 patients were treated with IVIG with a 100{\%} complete or partial response rate. Treatment was initiated at a dose of 2 g/kg (total dose, divided over 2-5 days) for 6 months of initial therapy. In each case where IVIG was used, maintenance infusions are required to preserve disease control. We highlight the long-term use of this medication in several cases. We discuss the potential therapeutic benefit of IVIG in this condition, where the pathophysiology of the disease is poorly understood, and underscore new data on the potential mechanism of action of IVIG therapy.",
author = "Marissa Blum and Fredrick Wigley and Laura Hummers",
year = "2008",
month = "1",
doi = "10.1097/MD.0b013e3181630835",
language = "English (US)",
volume = "87",
pages = "10--20",
journal = "Medicine",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Scleromyxedema

T2 - A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)

AU - Blum, Marissa

AU - Wigley, Fredrick

AU - Hummers, Laura

PY - 2008/1

Y1 - 2008/1

N2 - Scleromyxedema is a rare disease characterized by mucin deposition in skin and other organs and the production of a monoclonal IgG protein. Herein we describe our experience with a series of patients with this condition and specifically focus on the use of intravenous immunoglobulin (IVIG) for long-term management. We retrospectively reviewed the clinical manifestations of 10 patients evaluated at our center, highlighting the potential organ involvement. We found that systemic manifestations of the disease are common and often mimic those seen in systemic sclerosis. Eight of the 10 patients were treated with IVIG with a 100% complete or partial response rate. Treatment was initiated at a dose of 2 g/kg (total dose, divided over 2-5 days) for 6 months of initial therapy. In each case where IVIG was used, maintenance infusions are required to preserve disease control. We highlight the long-term use of this medication in several cases. We discuss the potential therapeutic benefit of IVIG in this condition, where the pathophysiology of the disease is poorly understood, and underscore new data on the potential mechanism of action of IVIG therapy.

AB - Scleromyxedema is a rare disease characterized by mucin deposition in skin and other organs and the production of a monoclonal IgG protein. Herein we describe our experience with a series of patients with this condition and specifically focus on the use of intravenous immunoglobulin (IVIG) for long-term management. We retrospectively reviewed the clinical manifestations of 10 patients evaluated at our center, highlighting the potential organ involvement. We found that systemic manifestations of the disease are common and often mimic those seen in systemic sclerosis. Eight of the 10 patients were treated with IVIG with a 100% complete or partial response rate. Treatment was initiated at a dose of 2 g/kg (total dose, divided over 2-5 days) for 6 months of initial therapy. In each case where IVIG was used, maintenance infusions are required to preserve disease control. We highlight the long-term use of this medication in several cases. We discuss the potential therapeutic benefit of IVIG in this condition, where the pathophysiology of the disease is poorly understood, and underscore new data on the potential mechanism of action of IVIG therapy.

UR - http://www.scopus.com/inward/record.url?scp=38349190093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349190093&partnerID=8YFLogxK

U2 - 10.1097/MD.0b013e3181630835

DO - 10.1097/MD.0b013e3181630835

M3 - Article

C2 - 18204366

AN - SCOPUS:38349190093

VL - 87

SP - 10

EP - 20

JO - Medicine

JF - Medicine

SN - 0025-7974

IS - 1

ER -